SEC For	rm 4																	
	FORM	4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549													OMB APPROVAL		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).					led pu	ursuan	t to Sectio	n 16(ES IN B a) of the Sec Investment	curiti	es Exchar	-	HIP	Estim	OMB Number: 3235-0 Estimated average burden hours per response:		3235-0287 n 0.5	
1. Name and Address of Reporting Person [*] Orlinger Klaus (Last) (First) (Middle)				= <u>H</u> 3.	100	KIPA P	har	ker or Tradii ma Inc. saction (Mor	[H	ООК]	(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) Chief Scientific Officer			wner			
C/O HOOKIPA PHARMA INC. 350 FIFTH AVENUE, 72ND FLOOR, SUITE 724 (Street) NEW YORK NY 10118				7240	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								Chief Scientific Officer 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State) (Zip)					Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
Table I - Non-Deriv 1. Title of Security (Instr. 3) 2. Trans. Date (Month/L)				sactio	on	2A. Deemed Execution Date, if any (Month/Day/Yea		a, 3. Transactic Code (Inst		4. Securi	of, or Beneficiall ities Acquired (A) or d Of (D) (Instr. 3, 4 and		5. Amoun	s Ily ollowing	Form	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							Code	v	Amount	(A) o (D)	Price	Transactie (Instr. 3 a				iiisti. 4)		
			Table II -						uired, Di s, option					Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title an of Securit Underlyin Derivative (Instr. 3 a	g Security	8. Price of Derivative Security (Instr. 5)	9. Numbo derivativ Securitie Beneficia Owned Followin Reported	re es ally g d	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				c	Code	v	(A)	(D)	Date Exercisable		xpiration ate Title Amount or Number of Shares			Transaction(s) (Instr. 4)				
Stock Option (Right to Buy)	\$1	04/14/2023			Α		194,200		(1)	0.	4/14/2033	Common Stock	194,200	\$0	194,2	200	D	

Explanation of Responses:

1. 25% of this option shall vest on February 15, 2024, with the remainder vesting in 12 equal quarterly installments thereafter.

/s/ Reinhard Kandera, as	
Attorney-in-Fact	

04/18/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.